Flash Glucose Monitoring Improves Glucose Control in People with Type 2 Diabetes Mellitus Receiving Anti-diabetic Drug Medication

Abstract

Objective To investigate the effects of Flash Glucose Monitoring (FGM) on glucose profile in people with Type 2 Diabetes Mellitus (T2DM) receiving anti-diabetic drug medication.

Methods This is a prospective non-randomized uncontrolled study. 111 people with T2DM were enrolled and received FGM for 14 days. There was no change of anti-diabetic medication during the 14 days. The plasma glucose concentration on day 2 was used as baseline and the day 13 was considered as study end point. The parameters to compare were mean plasma glucose (MPG), glucose variations, and incidence of hypoglycemia during the FGM period. The multivariate linear stepwise regression analysis was applied to determine the independent factors that affect MPG difference.

Results This study analyzed the data of a total of 111 people with T2DM (male 60 and female 51). The general clinical data of these patients were as follows: age: 65.0±6.7 years old; duration of diabetes: 11.6±6.8 years; HbA1c: 61.2±13.3 mmol/mol; body mass index (BMI): 25.2±3.2 kg/m². Using FGM, people with T2DM were able to change daily diet and exercise through which significant reductions in MPG on days 12 or 13 were achieved as compared with that of day 2 (P=0.04 or P=0.003, respectively). The glucose variations, such as standard deviation (SD) of plasma glucose, coefficient of variation (CV), and mean amplitude of glycemic excursion (MAGE), progressively declined starting from day 6 as compared with baseline (P=0.016, P=0.003, or P=0.012, respectively). The incremental area over the curve (AOC) of the hypoglycemia (<3.9 mmol/L) had a significant reduction starting from the day 3 (P=0.001). When people with T2DM were divided into 3 groups based on the tertile of HbA1c (high, middle, and low concentrations), the reduction of MPG in patients with high concentration of HbA1c were much larger than that in middle and low concentration group patients (P=0.001 for both). The incidence of hypoglycemia was improved in the low concentration group (P=0.017). The optimal frequency of scanning time required to maintain euglycemia was 11.7 times/day as calculated by the receiver operating characteristic (ROC) analysis.

Conclusion Using FGM to monitor glucose concentration at 11.7 times/day, people with T2DM can achieve a better glucose control in addition to anti-diabetic drug medication through changing daily diet and exercise, especially in patients with high concentration of HbA1c (>66.1 mmol/mol).

Key words

flash glucose monitoring - HbA1c - type 2 diabetes mellitus - self-glycemic management

Publication History

Received: 26 January 2019
Received: 30 July 2019

Accepted: 09 August 2019

Article published online:
28 August 2020

• References

• 1 Bao Y, Chen L, Chen L. et al. Chinese clinical guidelines for continuous glucose monitoring (2018 edition).. Diabetes Metab Res Rev. 2019; 35(6): e3152
• 2 Vincze G, Barner JC, Lopez D. Factors associated with adherence to self-monitoring of blood glucose among persons with diabetes.. Diabetes Educ 2004; 30: 112-125
• 3 Murata T, Tsuzaki K, Yoshioka F. et al. The relationship between the frequency of self-monitoring of blood glucose and glycemic control in patients with type 1 diabetes mellitus on continuous subcutaneous insulin infusion or on multiple daily injections.. J Diabetes Investig 2015; 6: 687-691
• 4 Bolinder J, Antuna R, Geelhoedduijvestijn P. et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: A multicentre, non-masked, randomised controlled trial.. Lancet 2016; 388: 2254-2263
• 5 Campbell F, Kordonouri O, Murphy N. et al. Freestyle libre use for self-management of diabetes in children and adolescents.. Diabetes 2017; 66 (Suppl. 1A) LB28-LB28
• 6 Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self-monitoring of blood glucose: Meta-analysis of randomised controlled trials using individual patient data.. BMJ 2011; 343: d3805
• 7 American Diabetes Association. Standards of medical care in diabetes-2013.. Diabetes Care 2013; 36 (Suppl 1) S11-S66
• 8 Chinese guideline for the prevention and treatment of type 2 diabetes mellitus (2017 edition). Chin J Diabetes Mellitus. 2018; 10: 4–67
• 9 Leelarathna L, Wilmot EG. Flash forward: a review of flash glucose monitoring.. Diabet Med. 2018; 35: 472-482
• 10 Bergenstal RM. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: The Ambulatory Glucose Profile (AGP).. Diabetes Technol Ther 2013; 15: 198-211
• 11 Antuna R. Consensus recommendations for the use of Ambulatory Glucose Profile in clinical practice.. Br J Diabetes Vasc Dis 2016; 14: 153
• 12 Haak T, Hanaire H, Ajjan R. et al. Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes.. Diabetes Ther 2017; 8: 573-586
• 13 Reddy M, Jugnee N, El LA. et al. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia.. Diabet Med. 2017 35. (Suppl 1).
• 14 Dover AR, Stimson RH, Zammitt NN. et al. Flash glucose monitoring improves outcomes in a type 1 diabetes clinic.. J Diabetes Sci Technol 2016; 11: 442-443
• 15 Mcknight JA, Gibb FW. Flash glucose monitoring is associated with improved glycaemic control but use is largely limited to more affluent people in a UK diabetes centre.. Diabet Med 2017; 34: 732-732
• 16 Dunn T, Xu Y, Hayter G. Evidence of a strong association between frequency of flash glucose monitoring and glucose control measures during real-world usage.. Diabetes Technol Ther 2017; 19 (Suppl. 1) A12-A12
• 17 Groot MD, Crick KA, Long M. et al. Lifetime duration of depressive disorders in patients with type 2 diabetes.. Diabetes Care 2016; 39: 2174-2181